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Paola Polverino,8 Andrea Bernardini,3 Gaia Pellitteri,3 Mariarosa Valente,3 Claudio Bertolotti,8
Benedetta Nacmias,10,11Giandomenico Maggiore,12 Tiziana Cavallaro,1 Paolo Manganotti,8
Gianluigi Gigli,3 Salvatore Monaco,1 Flavio Nobili2,13 and Gianluigi Zanusso1
*These authors contributed equally to this work.
In patients with suspected dementia with Lewy bodies, the detection of the disease-associated a-synuclein in easily accessible tissues
amenable to be collected using minimally invasive procedures remains a major diagnostic challenge. This approach has the potential to
take advantage of modern molecular assays for the diagnosis of a–synucleinopathy and, in turn, to optimize the recruitment and selec-
tion of patients in clinical trials, using drugs directed at counteracting a-synuclein aggregation. In this study, we explored the diagnostic
accuracy of a-synuclein real-time quaking-induced conversion assay by testing olfactory mucosa and CSF in patients with a clinical
diagnosis of probable (n¼ 32) or prodromal (n¼ 5) dementia with Lewy bodies or mixed degenerative dementia (dementia with Lewy
bodies/Alzheimer’s disease) (n¼6). Thirty-eight patients with non-a-synuclein-related neurodegenerative and non-neurodegenerative
disorders, including Alzheimer’s disease (n¼ 10), sporadic Creutzfeldt–Jakob disease (n¼ 10), progressive supranuclear palsy (n¼ 8),
corticobasal syndrome (n¼ 1), fronto-temporal dementia (n¼ 3) and other neurological conditions (n¼6) were also included, as con-
trols. All 81 patients underwent olfactory swabbing while CSF was obtained in 48 participants. At the initial blinded screening of olfac-
tory mucosa samples, 38 out of 81 resulted positive while CSF was positive in 19 samples out of 48 analysed. After unblinding of the
results, 27 positive olfactory mucosa were assigned to patients with probable dementia with Lewy bodies, five with prodromal demen-
tia with Lewy bodies and three to patients with mixed dementia, as opposed to three out 38 controls. Corresponding results of CSF
testing disclosed 10 out 10 positive samples in patients with probable dementia with Lewy bodies and six out of six with mixed demen-
tia, in addition to three out of 32 for controls. The accuracy among results of real-time quaking-induced conversion assays and clinical
diagnoses was 86.4% in the case of olfactory mucosa and 93.8% for CSF. For the first time, we showed that a-synuclein real-time
quaking-induced conversion assay detects a-synuclein aggregates in olfactory mucosa of patients with dementia with Lewy bodies and
with mixed dementia. Additionally, we provided preliminary evidence that the combined testing of olfactory mucosa and CSF raised
the concordance with clinical diagnosis potentially to 100%. Our results suggest that nasal swabbing might be considered as a first-line
screening procedure in patients with a diagnosis of suspected dementia with Lewy bodies followed by CSF analysis, as a confirmatory
test, when the result in the olfactory mucosa is incongruent with the initial clinical diagnosis.
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Introduction
Dementia with Lewy bodies (DLB) is a progressive neuro-
degenerative disease characterized by fluctuating cognitive
decline, visual hallucinations, parkinsonism, and rapid eye
movement sleep behaviour disorder. Although the diagno-
sis of probable DLB is supported by biomarkers of down-
stream neurodegeneration, such as dopamine transporter
SPECT imaging, I-123 metaiodobenzylguanidine myocar-
dial scintigraphy, and polysomnography, the diagnostic
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accuracy of these tests for DLB is still limited, at early
stages of the disease.1–3 Moreover, a reliable biomarker
for misfolded a-synuclein (a-syn) is demanding. Indeed, a
radiotracer for a-syn is not yet available as opposed to
Alzheimer’s Disease (AD), in which in vivo investigations
using radiotracers for beta-amyloid or tau, or CSF deter-
mination of biomarker (i.e. phospho-tau, total tau and
amyloid b42) levels provides information on the underly-
ing pathology. Despite promising expectations, enzyme-
linked immunosorbent assay (ELISA) assays for the detec-
tion of disease-associated a-syn in the CSF showed poor
specificity and sensitivity.4,5 Therefore, a great interest had
been focussed on detecting intraneural phosphorylated a-
syn (p-a-syn) deposition by immunohistochemistry in tissue
biopsies of skin, colonic submucosa or submandibular
glands of patients with DLB for ante-mortem diagnosis.6–8
However, the diagnostic accuracy of immunohistochemis-
try in detecting p-a-syn in peripheral tissue biopsies did
not provide consistent results among studies, as yet.9
More recently, the real-time quaking-induced conver-
sion (RT-QuIC) assay has been shown to reliably detect
misfolded a-syn in CSF and other peripheral tissues of
patients with a-synucleinopathies.10,11 Alpha-syn RT-
QuIC amplifies trace amount of pathological a-syn by
virtue of the ability of aggregated a-syn to convert the re-
combinant a-syn protein, forming amyloid fibrils which
enhance fluorescence of thioflavin T (ThT). In a previous
study, we tested CSF with RT-QuIC for a-syn in patients
with definite and clinical diagnosis of DLB obtaining a
diagnostic sensitivity and specificity of 92.9%, and
95.9%, respectively, in distinguishing DLB and DLB with
Alzheimer’s co-pathology (DLB/AD mixed dementia) from
non a-syn-related dementias.12 Similar results in CSF sam-
ples from patients with DLB, tested with a-syn RT-QuIC,
have been obtained also in other studies.13–17
In human prion disorders, we provided evidence that
prion RT-QuIC analysis of CSF and olfactory mucosa
(OM) samples tested separately provided a 100% specificity
and a sensitivity of 77–86% and 97–95%, respectively.18,19
However, the combination of RT-QuIC analysis in both tis-
sues raised the diagnostic accuracy to 100%.19 Although in
human prion disorders CSF analysis is an urgent and man-
datory test to exclude other treatable disorders, in slowly
progressive dementias, such as DLB, CSF analysis could be
postponed if a minimally invasive procedure such as nasal
swabbing would provide the same information.
Alpha-syn RT-QuIC assay on OM samples had been
explored in a single study in patients with Parkinson’s
disease (PD) or Multi System Atrophy (MSA) versus 18
controls with non-a-syn-related disorders.20 More recent-
ly, we showed that RT-QuIC assay is positive in OM of
44.4% of patients with iRBD.21 However, at present no
data are available on a-syn RT-QuIC testing in OM sam-
ples from patients with DLB.
In this study, we collected OM samples using nasal
swabbing from patients with probable, prodromal DLB
and DLB/AD mixed dementia (DLB group) and with
non-a-syn-related neurodegenerative or non-neurodegener-
ative disorders (non-a-syn NDs) and tested them by a-syn
RT-QuIC. We also analysed CSF samples to further val-
idate in another specimen the OM RT-QuIC results and
to determine the diagnostic accuracy in each of the two
tissues and in combination.
Materials and methods
Ethics statement and setting
The study was conducted according to the revised
Declaration of Helsinki and Good Clinical Practice guide-
lines. Informed consent was given by study participants
or the next of kin.
Five neurology units participated in the study:
University of Verona (UNIVR), University of Trieste
(UNITS), University of Udine (UNIUD), University of
Genova (UNIGE) and University of Florence (UNIFI).
OM ad CSF sample collections were performed according
to protocols approved by the Ethical Committees of each
neurology unit. Written informed consent for OM brush-
ing and lumbar puncture was obtained from each patient
or from legal representative.
Patients
Eighty-one patients were enrolled in the study UNIVR
(n¼ 32), UNITS (n¼ 10), UNIUD (n¼ 10), UNIGE
(n¼ 22), and UNIFI (n¼ 7) between Jan 2019 and July
2020. Clinical diagnosis was based on the established cri-
teria. OM samples obtained from 43 patients with prob-
able (n¼ 32) or prodromal DLB (n¼ 5) and DLB/AD
mixed dementia (n¼ 6) and 38 controls with a clinical
diagnosis of non-a-syn NDs, including patients with spor-
adic Creutzfeldt–Jakob disease (sCJD) (n¼ 10), AD
(n¼ 10), progressive supranuclear palsy (PSP) (n¼ 8), cor-
ticobasal syndrome (CBS) (n¼ 1), fronto-temporal demen-
tia (FTD) (n¼ 3) (two with behavioural variant and one
with non-fluent aphasia) and other neurological disorders
(n¼ 6), including, psychosis (n¼ 2), Down syndrome
(n¼ 1), vascular dementia (n¼ 1); mild cognitive impair-
ment (n¼ 1) and Arnold–Chiari malformation type 1
(n¼ 1). In particular, the diagnosis of DLB follows the
2017 McKeith criteria22 or the 2020 criteria for pro-
dromal DLB.23 Patients with DLB/AD mixed dementia
included DLB patients with a CSF biomarker profile of
AD.24 The diagnosis of AD was made according to the
2011 NIA-AA criteria for the dementia stage.25 PSP and
CBS diagnoses were assessed according to the established
diagnostic criteria.26,27 Demographic and main clinical
details are reported in Table 1. All patients underwent
pertinent brain imaging, as well other investigations sup-
porting the clinical diagnosis and to rule out other causes
of cognitive impairment.
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Study design
OM sample were collected from patients with DLB and
from controls with non a-syn NDs in different Neurology
units and sent to UNIVR for a-syn RT-QuIC testing.
Olfactory mucosa samples from each patient were
labelled with an anonymized code and temporary stored
at 4C, until the delivery. Conversely, after collection
CSF samples were frozen and sent subsequently. For
UNIVR, CSF and OM samples were anonymized by a
third party and RT-QuIC analyses were blinded to the
clinical diagnosis
Olfactory mucosa sample collection
and processing
Eighty-one patients were included in this study and
underwent nasal swabbing. The procedure was well
tolerated by all patients and no adverse events were
reported. Nasal swabbing procedure was performed in
all participants using flocked swabs (FLOQSwabsV
R
;
Copangroup, Brescia, Italy), as described previously.19
Otolaryngologists were trained by a tutorial video of the
procedure is available at: https://www.youtube.com/
watch?v¼wYb9W3u6uMY&t¼28s. Each nasal swabbing
procedure took around 5 min per patients. Exclusion cri-
teria included severe nasal cavity abnormalities, or infec-
tions. Coagulation disorder or anticoagulant/antiplatelet
drug intake or other medical conditions were not exclu-
sion criteria. One to four OM samples were collected
from each individual, depending on the patient’s tolerance
for the procedure. To minimize a potential bias in the
pre-analytical step, tubes and nasal swabs for nasal swab-
bing procedure were provided by UNIVR. Preparation,
processing and preservation of OM samples were stand-
ardized for all groups.
Following nasal swabbing, the swab was immediately
immersed in a 5 ml polypropylene tube containing 0.9%
saline, sealed, marked with a code and sent without any
personal identifiers to UNIVR within 48 h for a-syn RT-
QuIC analysis. Upon arrival, cellular material was disso-
ciated from the swab by vortexing the tubes for 1 min at
room temperature. Then, the swab was removed from
the tube, and cell suspension was pelleted by centrifuga-
tion at 2000g at 4C for 20 min. The supernatant was
almost completely removed, and the remaining pellet fro-
zen at 80C until assayed. Usually, a single swab would
provide a cell pellet with an approximate volume of 15
microliters.
CSF collection and evaluation of
biomarkers
Conversely, CSF samples were obtained by lumbar punc-
ture from 48 patients which included 10 patients with
probable DLB, 6 patients with DLB/AD mixed dementia
and 32 controls with non-a-syn NDs (Table 1). CSF sam-
ples were collected in polypropylene tubes and sent fro-
zen to UNIVR for a-syn RT-QuIC analysis. In 44 CSF
samples, biomarkers for AD were also determined and
included total-tau (T-tau), phosphorylated-tau (p-tau) and
Ab1–42 (Ab42) analyses using commercially available
ELISA kits (INNOTEST htau-Ag, INNOTEST p-tau181






















Gender M/F 23/9 3/2 3/3 7/3 5/5 4/4 0/1 3/0 2/4
Age (years) 73.9 6 6.0 75.4 6 4.0 66.3 6 9.6 69.3 6 9.6 66 6 16 73.5 6 5.0 70 72.0 6 1.6 53 6 24.4
MMSE score at
diagnosis





39.0 6 27.2 26.2 6 14.9 31.8 6 31.0 26.0 6 15.0 3.3 6 1.8 20.7 6 14.9 36 37.3 6 9.6 33.6 6 43
MMSE score at OM
brushing





















0/10 0/1 5/5 9/10 0/10 0/4 0 0/3 0/4
aAll CJD patients received a definite diagnosis.
bClinical diagnoses included: Psychosis (n¼ 2), Down syndrome (n¼ 1), vascular dementia (n¼ 1); mild cognitive impairment (n¼ 1) and Arnold-Chiari malformation type 1 (n¼ 1);
§CSF biomarkers were considered positive for AD. pathology when the ratio of Ab42 and p-tau was lower than 6.5 (see Ref.28) or when the ratio T-tau/Ab42 was lower than 0.52
(see Ref.29); N.E. denotes not evaluated; mo denotes month.
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and INNOTEST Ab42). CSF biomarkers were considered
positive for AD pathology when the ratio of Ab42 and
p-tau was lower than 6.5 or when the ratio T-tau/Ab42
was lower than 0.52.28,29
Expression and purification of
recombinant human a-synuclein
Recombinant a-syn was expressed and purified from the
periplasmic fraction as reported.30 Briefly, wild-type
human a-syn cDNA was cloned in the pET-28a plasmid
(Novagen) and transformed into Escherichia coli BL21
(DE3). Cell cultures (1 L) were grown at 37C to an OD
600 nm of 0.3–0.4 and the expression was induced with
0.1 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) for
5 h. Cells were collected by centrifugation, re-suspended
in 100 ml of osmotic shock buffer (30 mM Tris–HCl pH
7.2, 40% sucrose, 2 mM EDTA) and incubated for
10 min at room temperature. The cells were centrifuged
at 12 000 rpm, re-suspended in 90 ml of cold water with
37.5 ml of saturated MgCl2 solution and, after 5 min incu-
bation on ice, centrifuged again. The supernatant contain-
ing the periplasm proteins was boiled for 15 min and
cleared by centrifugation. The soluble fraction, enriched
in a-syn was subjected to ammonium sulphate precipita-
tion followed by extensively dialysis against 20 mM
Tris–HCl, pH 8.0. Further purification of a-syn was per-
formed by anion exchange chromatography loading the
sample on a Q-Sepharose column (GE Healthcare) equili-
brated with the same buffer and eluted with a 0–500 mM
linear gradient of NaCl. The purity of a-syn was checked
by SDS–PAGE. The protein was then dialysed against
10 mM Sodium Phosphate buffer pH 7.4, and stored at
80C until use.
Alpha-synuclein RT-QuIC analysis of
olfactory mucosa and cerebrospinal
fluid
We performed a-syn RT-QuIC assay as reported previ-
ously for CSF and OM except where indicated.12,21
For OM seeded reactions, we used 2 ll of diluted OM
in 98ml of Reaction Buffer composed of 100 mmol/l phos-
phate buffer (pH 8.2), 10 lmol/l ThT, and 0.05 mg/ml
human recombinant full length (1–140 aa) a-syn and
37 6 3 mg of 0.5-mm glass beads (Sigma). The plate was
then sealed with a plate sealer film (Nalgene Nunc
International) and then incubated at 30C in a BMG
FLUOstar Omega plate reader with cycles of 1 min shaking
(200 rpm double orbital) and 14 min rest. ThT fluorescence
measurements (450 6 10 nm excitation and 480 6 10 nm
emission; bottom read) were taken every 45 min.
In the case of CSF seeded reactions, 15 ml of undiluted
CSF was added 85 ml of reaction mix composed of
100 mmol/l phosphate buffer (pH 8.2), 10 lmol/l ThT,
0.05 mg/ml human recombinant full length (1–140 aa)
a-syn, 0.0075% sodium dodecyl sulphate (SDS) and
37 6 3 mg of 0.5-mm glass beads (Sigma). The reaction
plates were incubated at 30C in a BMG FLUOstar
Omega plate reader with cycles of 1 min shaking (200 rpm
double orbital) and 14 min rest. ThT fluorescence measure-
ments (450 6 10 nm excitation and 480 6 10 nm emission;
bottom read) were taken every 45 min.
The criteria for discriminating positive versus negative
RT-QuIC tests of CSF and OM are criteria similar to
those previously described for prion RT-QuIC analyses.18
Briefly, a ThT fluorescence threshold was calculated as
the average fluorescence during the initial 10 h of incuba-
tion, plus three standard deviations (SD) for OM samples
and 10 SD for CSF samples. A sample was considered
positive overall when at least two of four replicate wells
crossed this calculated threshold. When only one of the
quadruplicates crossed the threshold, the analysis was
repeated, and if the data were confirmed the sample was
considered as an undetermined negative. All the data
were normalized as previously described.18 The results of
RT-QuIC analysis were communicated to each Neurology
unit or to the third party and matched to the clinical
diagnosis.
Statistical analysis
RT-QuIC relative fluorescence responses were analysed
and plotted using the software Graphpad Prism 8.3. We
compared the mean relative ThT fluorescence and the lag
phase responses in OM and CSF samples from DLB
patients by either two-tailed unpaired t-test or by Mann–
Whitney U-test following ascertainment of normal distri-
bution of data by Shapiro–Wilk normality test.
We compared batch-to-batch difference in the mean
maximum ThT fluorescence values obtained in OM and
CSF from DLB group and non-a-syn NDs patients by
Kruskal–Wallis test with Dunn’s multiple comparisons
after the ascertainment of normal distribution of data by
Shapiro–Wilk normality test.
P values < 0.05 were considered statistically significant.
Agreement between OM, CSF and clinical diagnosis was
tested for significant differences by McNemar test, and
quantified with Cohen’s kappa (k).
Data availability
Data can be available upon request to the corresponding
author.
Results
Detection of a-syn seeds by a-syn
RT-QuIC assay
To establish the a-syn RT-QuIC assay for OM and CSF
we run an initial set of experiments using a small subset
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of OM and CSF samples from cases of definite DLB
and non-a-syn NDs. Seeding reactions were performed
by testing different concentrations of human
recombinant a-syn (0.01 mg/ml, 0.07 mg/ml, 0.05 mg/ml,
0.03 mg/ml) and we chose 0.05 mg/ml as the optimal
concentration for our current protocol. No increase in
fluorescence was observed in OM and CSFs from
control patients, while fluorescence above threshold
occurred within  25 h for OM and CSF samples,
in reactions seeded with DLB samples (Supplementary
Fig. 1).
Blinded RT-QuIC testing of OM and
CSF samples from patients with
DLB and with non-a-syn NDs
In a first round, we performed blinded analyses of 81
OM samples. Thirty-nine OM samples gave a positive
RT-QuIC response at 30 h while 42 remained negative
until 80 h (Fig. 1A and B). Although an OM sample
crossed the threshold it did not meet our criteria for RT-
QuIC positivity because only one of the quadruplicates
and was positive (Fig. 1A).
Figure 1 RT-QuIC blinded analysis of OM and CSF samples from patients with DLB and DLB/AD mixed dementia (DLB
group) and with non-a-synuclein-related disorders (non-a-syn NDs). (A) Dots represent the final average relative ThT fluorescence
readings obtained in OM for each individual case at 80 h. Bars show the average 6 SD for each case. The dashed line shows the fluorescence
threshold for a positive result. Magenta dots represent RT-QuIC positive OM while grey dots RT-QuIC negative. The X symbol represents
sample with one well positive out of four (B) Curves representative of a-syn RT-QuIC from that OM tested RT-QuIC positive (magenta trace)
and from OM tested RT-QuIC negative (grey trace). These curves are obtained from the average percentage of Thioflavin T (ThT)
fluorescence from four replicate reactions (normalized as described in the Materials and Methods section) with the means (thick lines) of
those averages and SDs (thin lines) shown as a function of RT-QuIC reaction time. (C) The triangles show the final average relative ThT
fluorescence readings obtained for each individual CSF by 80 h. Bars show the average 6 SD for type of case. Blue and grey triangles
represent RT-QuIC positive and negative CSF samples. The dashed line shows the fluorescence threshold for a positive result. The X symbol
represents CSF samples with one well positive out of four. (D) Curves representative of a-syn RT-QuIC performed on CSF samples that
tested positive (blue trace) and from CSF that tested negative (grey trace). Curves are obtained from the average percentage of ThT
fluorescence from four replicate reactions (normalized as described in the Materials and Methods section) with the means (thick lines) of
those average and SDs (thin lines) shown as a function of RT-QuIC reaction time.
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In a second round, 48 CSF samples were analysed by a-
syn RT-QuIC. In 26 samples, the initial seeding reaction
was observed at 25 h and the fluorescence gradually
increased to 80 h while in 22 CSF samples did not exceed
the designated positivity threshold (Fig. 1C and D). Seven
CSF samples crossed the threshold but were classified nega-
tive, since one well was positive out of four (Fig. 1C).
Concordance of RT-QuIC results of
OM and CSF with clinical diagnosis
Once all the OMs and CSFs were tested, the results were
unblinded. We learned that 27 RT-QuIC positive OM
samples were obtained from patients with probable DLB,
five with prodromal DLB and three with DLB/AD mixed
dementia while the remaining three positive samples were
from patients with non-a-syn NDs (Table 2 and Fig. 2A).
These included, one patient with AD, another with atyp-
ical parkinsonism and the third with psychosis (Table 2).
This first round of RT-QuIC testing showed an
accuracy of 86.4% (sensitivity 81.4%, specificity 92.1%).
We observed a good agreement between clinical
diagnoses and RT-QuIC OM testing (j¼ 0.729, 95% CI
0.582–0.876). The proportion of cases labelled as DLB
did not differ between clinical and laboratory diagnosis
(P¼ 0.227).
Table 2 Results of RT-QuIC assays of olfactory mucosa and cerebrospinal fluid samples






DLB group 35/43 16/16
Probable DLB 27/32 10/10
Prodromal DLB 5/5 –
DLB/AD mixed dementia 3/6 6/6







Rows in bold text indicate the totals for the DLB group and non-a-syn NDs patients.
Figure 2 Unblinded testing by a-synuclein RT-QuIC of OM and CSF samples from patients with DBL and DLB/AD mixed
dementia (DLB group) and non-a-syn NDs. (A) Final average relative ThT fluorescence from four replicate readings obtained from OM
of each individual cases with DLB group (magenta dots) and for each control (non-a-syn NDs) (grey dots) at 80 h. Bars show the
average 6 SD for each case. The dashed line shows the fluorescence threshold for a positive result. The X symbols indicate samples which
were tested twice and both times had only one well-crossing fluorescence threshold out of the four replicates. These samples were
considered as undetermined negative (see Materials and Methods section). (B) Final average relative ThT fluorescence from four replicate
readings obtained from CSF of DLB group of patients (blue triangles) and for each control (non-a-syn NDs) (grey triangles) at 80 h. Bars show
the average 6 SD for type of case. The X symbols are considered as undetermined negative.
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RT-QuIC analyses of CSF showed that the 19 out of 47
positive samples belonged to 10 patients with probable DLB
and six with DLB/AD mixed dementia while the remaining
three were from three patients with a clinical diagnosis of
AD, PSP and FTD, respectively (Table 2 and Fig. 2B).
Thus, RT-QuIC was positive in 16 out of 16 CSF sam-
ples from DLB group of patients and in three out of 31
from patients with non-a-syn NDs. with an accuracy of
93.8% (sensitivity 100% and specificity 90.6%). We
observed a high agreement between clinical diagnosis and
RT-QuIC CSF testing (j¼ 0.866, 95% CI 0.721–1.000),
that resulted in a similar proportion of identified cases
(P¼ 0.250).
In the control groups, one OM sample and seven CSF
samples had one well out of four replicate reactions with
fluorescence exceeding the threshold. These samples did
not meet the criteria of positivity and RT-QuIC analysis
in these samples was repeated. Upon second testing, the
results were the same and thus we considered these sam-
ples as “undetermined negative” (Supplementary Fig. 2).
The mean curves of fluorescence and the lag phase of
these samples showed a progressive increase but below
the threshold values within the 80 h timeframe.
RT-QuIC seeding activity in OM and
CSF
Then, we determined the relative percentage of maximum
fluorescence intensity in “positive” samples obtained in
DLB group in OM and CSF. This was approximately
70% for OM and 95% for CSF with a lag phase varying
between 30 and 25 h, respectively (Fig. 3). There was not
a significant difference in the RT-QuIC average percent-
age of the final ThT fluorescence value (P¼ 0.37 Mann–
Whitney test) or lag-time phase (P¼ 0.14 t-test) between
OM and CSF samples from patients with DLB (Fig. 3).
Batch-to-batch assay reproducibility
We tested OM and CSF samples from cases with definite
DLB and with non-a-syn NDs by using three different
batches of human recombinant a-syn, as substrate of
reaction. After normalization, we did not observe a sig-
nificant difference in the percentage of maximal ThT
fluorescence values, among batches in both CSF and OM
samples (Supplementary Fig. 3).
Evaluation of diagnostic reliability of
RT-QuIC results when OM and CSF
are combined
In 16 patients and 32 controls, both OM and CSF speci-
mens were available, thus the diagnostic accuracy of RT-
QuIC was analysed by combining the results obtained in
tissues (Table 3). Five OM samples from DLB group of
patients were RT-QuIC negative but the CSFs from the
same patients were positive (Table 3). Conversely, three
false-positive OMs from patients with non-a-syn NDs
Figure 3 RT-QuIC detection of a-synuclein seeding activity in patients with DLB and non-a-syn NDs with both OM and CSF
samplings. (A) Traces represent the average percentage of thioflavin T (ThT) fluorescence readings from four replicate reactions
(normalized as described in the Materials and Methods section), determined in OM (magenta trace) and CSF (blue trace) samples from
patients with DLB and DLB/AD mixed dementia (DLB). The means (thick lines) with standard deviations (thin lines) of those averages are
shown as a function of RT-QuIC reaction time. (B, C) Final fluorescence values in (B) and lag-phase in (C) of a-syn RT-QuIC positive OM and
CSF samples. Samples are grouped in four different classes (OM DLB group, magenta dots, CSF DLB group, blue triangles, OM non-a-syn
NDs grey dots and CSF non-a-syn NDs grey triangles). Data points in (B), represent the average percent fluorescence value from four
replicate readings obtained for each individual case at 80 h and bars show the mean 6 SD for type of case. Data points in (C) show hours
required from the mean percentage of ThT fluorescence value from four replicate readings to exceed the threshold for individual cases and
bars show the mean 6 SD for type of case.
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had a negative CSF and included one patient with AD,
one with mild cognitive impairment and another with
CBS. No significant differences between RT-QuIC assay
in OM and CSF and clinical diagnoses were observed
(P¼ 0.227) albeit agreement was moderate (j ¼ 0.498,
95% CI 0.247–0.749).
Although the RT-QuIC sensitivity in CSF was 100%,
three CSF specimens from patients with non-a-syn NDs
tested positive but their OM samples were negative and
included one patient with a clinical diagnosis of AD an-
other with PSP and one with FTD (Table 3).
In conclusion, when the results of RT-QuIC in OM
and CSF results were combined the diagnostic accuracy
increased to 100%.
Discussion
Clinical diagnosis of DLB is still a challenge and the
availability of diagnostic assays that detect pathological
a-syn in biological specimens of patients with DLB have
relevant clinical and potentially therapeutic implications.31
This study aimed at defining the best diagnostic strategy
for the identification of pathological a-syn, using the a-
syn RT-QuIC assay, in the “optimal diagnostic tissue”
such as olfactory mucosa or CSF.
To date, several studies have demonstrated the presence
of p-a-syn in skin and lip biopsies from patients with a
clinical diagnosis of DLB by immunohistochemistry, show-
ing a sensitivity ranging from 100% to 50% and a specifi-
city from 100% to 97%. However, tissue biopsies are
invasive, requiring multiple samplings and the accuracy of
immunohistochemistry in detecting p-a-syn is variable
among studies.6–8 Taking advantages of nasal swabbing,
we collected OM samples using this rapid, simple proced-
ure which does not require patient preparation or interrup-
tion of anticoagulant therapy and does not damage the
olfactory function. Since the olfactory mucosa is
approximately 2.5 cm squared and the swab surface is
2 cm in length, the swab comes in contact with a large
part of the olfactory epithelium allowing for an efficient
OM collection. Therefore, unlike other peripheral tissue
biopsies, a successful sampling of OM is always expected.
Of course, RT-QuIC assays have revolutionized the
diagnostic approach not only in human prion disorders
but also in other proteinopathies and in particular in a-
synucleinopathies.32,33 Previous studies showed that a-syn
RT-QuIC detects a-syn aggregates in CSF of patients
with DLB, with high diagnostic accuracy.12–17
Here, we show for the first time that OM samples are
a-syn RT-QuIC positive in 35 out of 43 patients with a
clinical diagnosis of DLB and in three with non-a-syn
NDs with a sensitivity and specificity of 81.4% and
92.1%, respectively. Compared to the previously reported
RT-QuIC results in OM of patients with PD and MSA,
and iRBD, the RT-QuIC sensitivity in DLB is apparently
higher.20,21 This finding might be related to the detection
of a-syn deposition in the olfactory neuroepithelium of
DLB individuals.34
Notably, in all patients with prodromal DLB, OM RT-
QuIC resulted positive providing evidence that the pro-
cess of a-syn seeding aggregation might be revealed at
early disease stage. However, given the relative low num-
ber of investigated patients, further studies are needed to
confirm whether OM swabbing might be considered a re-
liable diagnostic assay in this group of patients.
Three positive OMs were assigned to patients with
non-a-syn NDs but a similar result was also reported in
OM from patients with atypical parkinsonism.20
Although, the detection of a-syn seeding reaction in OM
from patient with AD might argue on the presence of a-
syn co-pathology, the positivity in the OM of a relatively
young patient with psychosis should be interpreted with
caution and thus deserving of clinical follow-up.
We showed that RT-QuIC testing of CSF correctly
identifies DLB patients with 100% sensitivity and 90.3%
Table 3 Patients with olfactory mucosa only and both olfactory mucosa and cerebrospinal fluid samples analysed by
a-syn RT-QuIC
Clinical diagnosis OM only (33) Patients with both OM and CSF (16)








DLB-Group (43) 24/27 11/16 – 5 –
Probable DLB (32) 19/22 8/10 – 2 –
DLB/AD mixed dementia (6) – 3/6 – 3 –
Prodromal DLB (5) 5/5 – – – –
Non-a-syn NDs (38) 0/6 0/32 3 3 26
CJD (10) – 0/10 – – 10
AD (10) – 0/10 1a 1a 8
PSP (8) 0/2 0/6 1a 1a 4
CBS (1) – 0/1 – – 1
FTD (3) – 0/3 – 1 2
Others (6) 0/4 0/2 1 – 1
aThis positive sample does not belong to the same patient.
Rows in bold text indicate the totals for the DLB group and non-a-syn NDs patients.
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specificity, in line with previous studies.12–17 It should be
noted that in patients with a clinical diagnosis of DLB/
AD mixed dementia and CSF biomarkers with AD
profile, the CSF was positive in all cases indicating that
a-syn RT-QuIC is a reliable assay for detecting a-syn
aggregates.12,35 These findings are in line with our own
previous study on a-syn RT-QuIC analysis of 15 CSF
samples obtained from pathologically confirmed cases of
DLB/AD mixed pathology where we found a positive
RT-QuIC for a-syn in 14 CSF analysed.12
In both OM and CSF, we found a considerable agree-
ment between clinical diagnoses and RT-QuIC assay. In
particular, the sensitivity of CSF was higher compared to
OM (100% versus 81.4%) while the specificity was com-
parable in CSF versus OM (90.3% versus 92.1%).
Indeed, the 100% concordant results of RT-QuIC in CSF
samples analysis of DLB group argue that positivity in
the three controls with AD, PSP and FTD might be
related to the presence of coincident a-syn aggregates, as
also observed in previous studies.16,17 As such, neuropa-
thologic studies reported a variable frequency of Lewy
bodies in cases of AD, PSP and FTLD indicating that the
concomitant deposition of a-syn and tau aggregates is a
rather common observation.36
Our strategy of “double tissue a-syn RT-QuIC testing”
from the same patient, by testing of OM first and subse-
quently CSF, as a confirmatory analysis showed 100%
concordance with the clinical diagnosis when both speci-
mens are considered. However, we could perform this kind
of combined analysis in approximately half of patients
with DLB. In particular, a confirmatory CSF analysis could
not be verified in three DLB patients with RT-QuIC nega-
tive OM samples because CSF samples were not available.
Of course, lack of both OM and CSF specimens in all
patients represents a limitation of the present study and
additional investigations on a larger cohort of patients
are needed. However, these preliminary data indicate that
testing both OM and CSF would be a promising ap-
proach to improve the refinement of intra-vitam diagnosis
in patients with suspected DLB or DLB/AD mixed de-
mentia, with the limitation that these analyses do not dis-
sect Parkinson’s dementia from DLB diagnoses.
In conclusion, we demonstrated that a gentle procedure
such as OM swabbing detects a-syn aggregates in OMs
with a considerable diagnostic robustness. Conversely,
CSF might be considered as an ancillary test to be ana-
lysed in the absence of a concordance between clinical
diagnosis and RT-QuIC results. Therefore, we envision
OM RT-QuIC testing as a technique that could be used
to select patients for clinical trials aimed at developing
drugs that target a-syn aggregation.31
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